Related Experiment Video
Updated: Apr 28, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
A CD30(-) Transformed Mycosis Fungoides Case Responding Very Well to Systemic Bexarotene and Methotrexate
Ilkin Zindanci1, Mukaddes Kavala1, Zafer Turkoğlu1
1Istanbul Medeniyet University, Goztepe Research and Training Hospital, Istanbul, Turkey.
Abstract:
The course of mycosis fungoides (MF) is indolent except when transformation to a large T-cell lymphoma occurs. The diagnosis of transformed MF relies on the presence of more than 25% of large cells on biopsy of an MF lesion. Treatment of transformed MF is a major challenge as these patients have poor outcome. Here, we report a 61-year-old man presenting with tumoral ulcer on the plantar area of the foot who was diagnosed cutaneous CD30(-) large cell transformed MF and treated with systemic methotraxate and bexarotene therapy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
